ProCE Banner Activity

Expert Insights Into Testing and Treatment for HER2-Expressing Solid Tumors

Clinical Thought

Access this engaging commentary containing insights from leading medical oncology and pathology faculty on key questions regarding testing for and treating HER2-expressing solid tumors, with a focus on GI cancers and NSCLC.

Released: May 14, 2025

Expiration: May 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

AstraZeneca

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals

Faculty Disclosure

Primary Author

James M. Cleary, MD, PhD: consultant/advisor/speaker: Gilead; researcher: Arcus, GlaxoSmithKline, Merck, Pyxis; data and safety monitoring committee: AstraZeneca.

Yin (Rex) Hung, MD, PhD, has no relevant financial relationships to disclose.

Lei Zhao, MD, PhD: researcher: Incyte.